Last $1.51 USD
Change Today -0.05 / -3.21%
Volume 74.0K
As of 8:10 PM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

durect corporation (DRRX) Snapshot

Open
$1.56
Previous Close
$1.56
Day High
$1.56
Day Low
$1.50
52 Week High
02/7/14 - $2.69
52 Week Low
08/14/13 - $1.00
Market Cap
166.9M
Average Volume 10 Days
143.8K
EPS TTM
$-0.19
Shares Outstanding
110.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DURECT CORPORATION (DRRX)

durect corporation (DRRX) Related Businessweek News

No Related Businessweek News Found

durect corporation (DRRX) Details

DURECT Corporation, a specialty pharmaceutical company, is engaged in the development of pharmaceutical products based on its proprietary drug delivery technology platforms in the United States and internationally. It focuses on the development of various products for the treatment of various chronic and episodic disease areas, such as pain, central nervous system disorders, metabolic disorders, cardiovascular disease, and other chronic diseases. The company’s products comprise ALZET product line that consists of osmotic pumps and accessories, which are used for experimental research in mice, rats, and other laboratory animals; and a range of standard and custom biodegradable polymers that are used as raw materials in the pharmaceutical and medical devices under the brand name of LACTEL. Its products also include REMOXY, an oral oxycodone gelatin capsule for chronic pain; POSIDUR, a formulation of bupivacaine for the treatment of post-surgical pain that has completed Phase III clinical study; ELADUR, a Phase II transdermal bupivacaine patch intended to provide delivery of bupivacaine; and TRANSDUR-Sufentanil that has completed Phase II transdermal sufentanil patch, which is intended to provide delivery of sufentanil. In addition, the company’s products pipeline comprises ORADUR-based opioids, including hydrocodone and hydromorphone that are in Phase I clinical trials for the treatment of pain; oxymorphone, an ORADUR-based opioid for which IND has been accepted by the FDA; ORADUR-ADHD, a drug candidate in Phase I clinical trial for the treatment of attention deficit hyperactivity disorder; and Relday, an injectable risperidone product in Phase I clinical trial used to treat the symptoms of schizophrenia and bipolar I disorder. It has strategic agreements with various companies, such as Pain Therapeutics, Inc.; Pfizer Inc.; Zogenix, Inc.; Hospira, Inc.; and Nycomed Danmark ApS. The company was founded in 1998 and is headquartered in Cupertino, California.

99 Employees
Last Reported Date: 05/2/14
Founded in 1998

durect corporation (DRRX) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $450.7K
Co-Founder, Chairman and Chief Scientific Off...
Total Annual Compensation: $248.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $310.5K
Executive Vice President of Pharmaceutical Sy...
Total Annual Compensation: $298.2K
Compensation as of Fiscal Year 2013.

durect corporation (DRRX) Key Developments

DURECT Corporation Enter into Loan and Security Agreement with Oxford Finance LLC

DURECT Corporation announced that it had entered into a Loan and Security Agreement with Oxford Finance LLC, pursuant to which Oxford agreed to make a term loan to the company in the principal amount of $20 million. The loan has a fixed interest rate of 7.95% per annum with interest only payments for the first 18 months and repayment of all principal and interest by July 1, 2018. In addition, the company paid a $150,000 facility fee at closing and, at maturity or earlier termination, the company must pay Oxford an additional one-time payment equal to 8% of the initial principal amount of the term loan. The company may use the proceeds of the Loan Agreement for general working capital and to fund its business requirements.

DURECT Corporation Presents at 25th Annual WSAF Institutional Investor Conference, Jun-19-2014 10:35 AM

DURECT Corporation Presents at 25th Annual WSAF Institutional Investor Conference, Jun-19-2014 10:35 AM. Venue: The University Club, 1 W. 54th Street, New York, NY 10019, United States. Speakers: Matthew J. Hogan, Chief Financial Officer, Principal Accounting Officer and Secretary.

DURECT Corporation Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2014

DURECT Corporation reported unaudited earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported total revenue of $6,293,000 compared to $4,153,000 a year ago. Operating loss was $3,602,000 compared to $5,195,000 a year ago. Net loss was $3,600,000 or $0.03 per basic and diluted share compared to $5,183,000 or $0.05 per basic and diluted share a year ago. Excluding all deferred revenue recognized for fees from the agreements, like with Zogenix and Impax, revenue from R&D collaborations was $1.4 million in the first quarter 2014 as compared to $0.9 million in the first quarter last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DRRX:US $1.51 USD -0.05

DRRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cosmo Pharmaceuticals SpA SFr.186.50 CHF -1.10
Depomed Inc $11.77 USD +0.25
Elite Pharmaceuticals Inc $0.34 USD -0.0141
Supernus Pharmaceuticals Inc $9.18 USD -0.05
Veloxis Pharmaceuticals A/S kr1.99 DKK -0.01
View Industry Companies
 

Industry Analysis

DRRX

Industry Average

Valuation DRRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.9x
Price/Book 5.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DURECT CORPORATION, please visit www.durect.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.